FI952267A0 - Koostumuksia sytokiiniaktiivisuuden säätelyyn - Google Patents

Koostumuksia sytokiiniaktiivisuuden säätelyyn

Info

Publication number
FI952267A0
FI952267A0 FI952267A FI952267A FI952267A0 FI 952267 A0 FI952267 A0 FI 952267A0 FI 952267 A FI952267 A FI 952267A FI 952267 A FI952267 A FI 952267A FI 952267 A0 FI952267 A0 FI 952267A0
Authority
FI
Finland
Prior art keywords
host
compositions
sulfated
acetylated
substances
Prior art date
Application number
FI952267A
Other languages
English (en)
Swedish (sv)
Other versions
FI952267A (fi
Inventor
Irun R Cohen
Ofer Lider
Liora Cahalon
Oded Shoseyov
Raanan Margalit
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of FI952267A0 publication Critical patent/FI952267A0/fi
Publication of FI952267A publication Critical patent/FI952267A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
FI952267A 1992-11-10 1995-05-10 Koostumuksia sytokiiniaktiivisuuden säätelyyn FI952267A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97475092A 1992-11-10 1992-11-10
US9673993A 1993-07-23 1993-07-23
PCT/US1993/010868 WO1994011006A1 (en) 1992-11-10 1993-11-09 Compositions for the regulation of cytokine activity

Publications (2)

Publication Number Publication Date
FI952267A0 true FI952267A0 (fi) 1995-05-10
FI952267A FI952267A (fi) 1995-07-10

Family

ID=26792027

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952267A FI952267A (fi) 1992-11-10 1995-05-10 Koostumuksia sytokiiniaktiivisuuden säätelyyn

Country Status (18)

Country Link
EP (2) EP0669827B1 (fi)
JP (1) JPH08506322A (fi)
CN (1) CN1093904A (fi)
AT (1) ATE201327T1 (fi)
AU (2) AU686581B2 (fi)
CA (1) CA2149116A1 (fi)
DE (2) DE69330252T2 (fi)
FI (1) FI952267A (fi)
HR (1) HRP931389A2 (fi)
HU (1) HUT70945A (fi)
IL (1) IL107563A (fi)
NO (1) NO951822L (fi)
NZ (1) NZ258367A (fi)
PL (1) PL309001A1 (fi)
SI (1) SI9300586A (fi)
TW (1) TW257678B (fi)
WO (1) WO1994011006A1 (fi)
YU (1) YU71393A (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750207B1 (en) 1992-05-01 2004-06-15 Yeda Research And Development Co. Ltd. Compositions for the regulation of cytokine activity
HUT70945A (en) * 1992-11-10 1995-11-28 Yeda Res & Dev Compositions for the regulation of cytokine activity contg. oligosaccharides and process to prepare them
CA2435637A1 (en) 2001-01-23 2002-08-01 Massachusetts Institute Of Technology Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
US7285536B2 (en) 2001-12-05 2007-10-23 Yeda Research And Development Co., Ltd. Anti-cancer therapeutic compounds
ITMI20021294A1 (it) * 2002-06-12 2003-12-12 Inalco Spa Polisaccaridi batterici o-solfatati e loro uso
EP1731131A1 (en) * 2004-03-29 2006-12-13 Kringle Pharma Inc. Hgf production accelerator containing heparin-like oligosaccharide
ITMI20091445A1 (it) * 2009-08-07 2011-02-08 Inalco S P A A Socio Unico Derivati semi-sintetici del polisaccaride k5 per la prevenzione ed il trattamento del danno tissutale associato a ischemia e/o riperfusione
CA3174662A1 (en) 2011-09-08 2013-03-14 Novozymes Bioag A/S Seed treatment methods and compositions
AU2012308443B2 (en) 2011-09-14 2017-05-04 Novonesis Plant Biosolutions A/S Use of lipochito-oligosaccharides and/or chito oligosaccharides in combination with phosphate-solubilizing microorganisms to enhance plant growth
CN107258790A (zh) 2011-09-23 2017-10-20 诺维信生物农业公司 用于增强植物生长的壳寡糖和方法
CN102824352B (zh) * 2011-10-11 2013-09-04 泸州医学院 一种双糖化合物在制备抗肿瘤药物中的用途
CN109730006B (zh) * 2019-03-19 2022-10-18 西华大学 提高动物黑色素含量的方法
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
BR112022018200A2 (pt) 2020-03-12 2022-11-29 Sydney David Cullis Hill Tratamento para infecção por coronavírus e toxicidade de citocinas associadas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4818816A (en) * 1981-04-28 1989-04-04 Choay, S.A. Process for the organic synthesis of oligosaccharides and derivatives thereof
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
FR2538404B1 (fi) * 1982-12-28 1985-08-23 Anic Spa
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
FR2597484B1 (fr) * 1986-04-17 1988-12-23 Sanofi Sa Glycosaminoglycanes de type heparine ou heparane-sulfate dotes d'une activite sur la division et la differentiation cellulaires, leur preparation et leurs applications therapeutiques.
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
JPH0818993B2 (ja) * 1989-11-28 1996-02-28 キッセイ薬品工業株式会社 プロスタグランジンｉ▲下２▼産生増強剤
BE1004029A6 (nl) * 1990-11-22 1992-09-08 Mol Omer De Farmaceutische samenstelling en farmaceutische set voor het behandelen van kanker.
AU668865B2 (en) * 1991-05-02 1996-05-23 Irun R. Cohen Compositions for the prevention and/or treatment of pathological processes
HUT70945A (en) * 1992-11-10 1995-11-28 Yeda Res & Dev Compositions for the regulation of cytokine activity contg. oligosaccharides and process to prepare them

Also Published As

Publication number Publication date
NZ258367A (en) 1997-02-24
EP0669827A4 (en) 1996-08-28
AU5599394A (en) 1994-06-08
EP1095657A2 (en) 2001-05-02
NO951822D0 (no) 1995-05-09
EP0669827A1 (en) 1995-09-06
IL107563A0 (en) 1994-02-27
FI952267A (fi) 1995-07-10
HU9501373D0 (en) 1995-06-28
EP0669827B1 (en) 2001-05-23
YU71393A (sh) 1997-05-28
TW257678B (fi) 1995-09-21
DE69334102D1 (de) 2007-02-22
HRP931389A2 (en) 1995-04-30
AU6478398A (en) 1998-06-25
DE69330252T2 (de) 2002-02-07
EP1095657B1 (en) 2007-01-10
NO951822L (no) 1995-06-29
DE69330252D1 (de) 2001-06-28
CN1093904A (zh) 1994-10-26
ATE201327T1 (de) 2001-06-15
CA2149116A1 (en) 1994-05-26
AU686581B2 (en) 1998-02-12
SI9300586A (en) 1994-09-30
WO1994011006A1 (en) 1994-05-26
HUT70945A (en) 1995-11-28
IL107563A (en) 2006-12-31
DE69334102T2 (de) 2007-10-18
AU699624B2 (en) 1998-12-10
JPH08506322A (ja) 1996-07-09
PL309001A1 (en) 1995-09-18
EP1095657A3 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
FI952267A0 (fi) Koostumuksia sytokiiniaktiivisuuden säätelyyn
CA2118121C (en) Methods and compositions for the treatment of diseases with interferon while reducing side effects
EP0876143A4 (en) TUMORNROSE FACTOR ALPHA (TNF-ALPHA) INHIBITING MEDICINAL PRODUCTS
EP0625991A4 (en) IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF FROM LEUKOCYTES OF THE HUMAN PERIPHERAL BLOOD.
DE69530389D1 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
AU3876295A (en) Hypolipidemic benzothiazepines
IL105219A0 (en) Cyclohexane-ylidene compounds and pharmaceutical compositions containing them
NZ251320A (en) Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions
GEP20002297B (en) Alpha-Substituted Pyrimidine-Thioalhyl and Alkyl-Ether Compounds, Method for Treatment of Individual Infected with the Immunodeficiency Virus
MX9708611A (es) Compuestos de dialquiltiacumicina.
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
CA2037779A1 (en) Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t
Kirby Vancomycin therapy in severe staphylococcal infections
CANTELL et al. IFN-γ enhances production of IFN-α in human macrophages but not in monocytes
Tupik et al. Upping the “Anti-” for arthritis: Antimicrobial defenses through anti-inflammatory NOD-like Receptor NLRX1 during Lyme disease
CA2078805A1 (en) Cytokine Preparation
RU95113594A (ru) Композиции для регулирования активности цитокина
DE69109933D1 (de) Verwendung von Mizoribin zur Behandlung oder Vorbeugung der Multiplen Sklerose.
Dupuy Natural resistance against mouse hepatitis virus 3
Roekke et al. Endotoxin and cytokines in plasma and clinical manifestations during treatment of septicaemia with imipenem or cefuroxime/metronidazole
RU93054957A (ru) Способ получения растительного биологически активного полисахарида
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
WO1994008474A3 (en) Medical food and method of administration
CA2268525A1 (en) The use of growth hormone as an aid for hypothermia

Legal Events

Date Code Title Description
FD Application lapsed